FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803404900> ?p ?o ?g. }

• W2803404900 endingPage "525" @default.
• W2803404900 startingPage "511" @default.
• W2803404900 abstract "Background Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population. Methods STRATOS 1 and STRATOS 2 were randomised, double-blind, parallel-group, placebo-controlled, phase 3 clinical trials that enrolled participants aged 12–75 years with severe asthma that was inadequately controlled despite use of inhaled corticosteroids (≥500 μg per day fluticasone or equivalent) and a long-acting β2 agonist (but not oral corticosteroids). STRATOS 1 was done at 246 sites in 14 countries, and STRATOS 2 was done at 242 sites in 13 countries. In STRATOS 1, participants were randomly assigned (2:1) to receive tralokinumab 300 mg or matching placebo subcutaneously every 2 weeks or every 4 weeks for 52 weeks. In STRATOS 2, participants were randomly assigned (1:1) to receive tralokinumab 300 mg or matching placebo subcutaneously every 2 weeks for 52 weeks. STRATOS 1 attempted to identify a biomarker-positive population with enhanced tralokinumab benefit, which was then tested in STRATOS 2. The primary endpoint was the annualised asthma exacerbation rate (AAER) reduction at week 52 in the all-comers population for STRATOS 1 and in the biomarker-positive population for STRATOS 2. All efficacy analyses for both trials were done on the full analysis set by an intention-to-treat approach. The safety analysis set comprised any participant who received the investigational drug and was categorised by treatment received. These trials are registered with ClinicalTrials.gov, numbers NCT02161757 (STRATOS 1) and NCT02194699 (STRATOS 2), and with the EU Clinical Trials Register, EudraCT 2013-005614-35 (STRATOS 1) and EudraCT 2013-005615-27 (STRATOS 2). Findings STRATOS 1 was done between June 13, 2014, and Feb 28, 2017. 1207 participants were randomly assigned and 1202 treated as follows: tralokinumab every 2 weeks (n=398), tralokinumab every 4 weeks (n=404), or placebo (n=400). STRATOS 2 was done between Oct 30, 2014, and Sept 21, 2017. 856 participants were randomly assigned and 849 treated as follows: tralokinumab every 2 weeks (n=427) and placebo every 2 weeks (n=422). In the STRATOS 1 all-comers population, tralokinumab every 2 weeks did not significantly reduce AAER compared with placebo (7·0% reduction [95% CI −20·8 to 28·4]; rate ratio 0·93 [95% CI 0·72 to 1·21]; p=0·59). Baseline fractional exhaled nitric oxide (FENO) 37 ppb or greater was identified as the preferred biomarker in STRATOS 1; in FENO-high participants, tralokinumab every 2 weeks (n=97) reduced AAER by 44·0% (95% CI 6·0 to 66·0; rate ratio 0·56 [95% CI 0·34 to 0·94]; p=0·028) compared with placebo (n=102). In the STRATOS 2 FENO-high population, tralokinumab every 2 weeks (n=108) did not significantly improve AAER (15·8% reduction [95% CI −33·7 to 47·0]; rate ratio 0·84 [95% CI 0·53 to 1·34]; p=0·47) compared with placebo (n=121). The safety profile was consistent with that of previous tralokinumab trials. Interpretation Tralokinumab reduced AAER in participants with severe asthma with baseline FENO 37 ppb or higher in STRATOS 1, but not in STRATOS 2. These inconsistent effects on AAER do not support a key role for interleukin 13 in severe asthma exacerbations. Funding AstraZeneca." @default.
• W2803404900 created "2018-06-01" @default.
• W2803404900 creator A5020755019 @default.
• W2803404900 creator A5021070456 @default.
• W2803404900 creator A5031562823 @default.
• W2803404900 creator A5048320859 @default.
• W2803404900 creator A5054815299 @default.
• W2803404900 creator A5058725005 @default.
• W2803404900 creator A5068913631 @default.
• W2803404900 creator A5082888399 @default.
• W2803404900 date "2018-07-01" @default.
• W2803404900 modified "2023-10-10" @default.
• W2803404900 title "Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials" @default.
• W2803404900 cites W1506450640 @default.
• W2803404900 cites W161823661 @default.
• W2803404900 cites W1977264840 @default.
• W2803404900 cites W1995853267 @default.
• W2803404900 cites W2008044944 @default.
• W2803404900 cites W2013105339 @default.
• W2803404900 cites W2026044056 @default.
• W2803404900 cites W2032110591 @default.
• W2803404900 cites W2043943442 @default.
• W2803404900 cites W2052951012 @default.
• W2803404900 cites W2054606150 @default.
• W2803404900 cites W2074537181 @default.
• W2803404900 cites W2098276532 @default.
• W2803404900 cites W2104852612 @default.
• W2803404900 cites W2124566107 @default.
• W2803404900 cites W2125805192 @default.
• W2803404900 cites W2130939988 @default.
• W2803404900 cites W2138355864 @default.
• W2803404900 cites W2153034426 @default.
• W2803404900 cites W2153395214 @default.
• W2803404900 cites W2153642908 @default.
• W2803404900 cites W2161325421 @default.
• W2803404900 cites W2168421693 @default.
• W2803404900 cites W2181161363 @default.
• W2803404900 cites W2299711638 @default.
• W2803404900 cites W2335783271 @default.
• W2803404900 cites W2342693354 @default.
• W2803404900 cites W2373523945 @default.
• W2803404900 cites W2511120040 @default.
• W2803404900 cites W2513258422 @default.
• W2803404900 cites W2515900781 @default.
• W2803404900 cites W2550032140 @default.
• W2803404900 cites W2559769990 @default.
• W2803404900 cites W2578016795 @default.
• W2803404900 cites W2611091259 @default.
• W2803404900 cites W2740279901 @default.
• W2803404900 cites W2752584372 @default.
• W2803404900 cites W2753448513 @default.
• W2803404900 cites W2790027323 @default.
• W2803404900 cites W2804085823 @default.
• W2803404900 doi "https://doi.org/10.1016/s2213-2600(18)30184-x" @default.
• W2803404900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29792288" @default.
• W2803404900 hasPublicationYear "2018" @default.
• W2803404900 type Work @default.
• W2803404900 sameAs 2803404900 @default.
• W2803404900 citedByCount "165" @default.
• W2803404900 countsByYear W28034049002018 @default.
• W2803404900 countsByYear W28034049002019 @default.
• W2803404900 countsByYear W28034049002020 @default.
• W2803404900 countsByYear W28034049002021 @default.
• W2803404900 countsByYear W28034049002022 @default.
• W2803404900 countsByYear W28034049002023 @default.
• W2803404900 crossrefType "journal-article" @default.
• W2803404900 hasAuthorship W2803404900A5020755019 @default.
• W2803404900 hasAuthorship W2803404900A5021070456 @default.
• W2803404900 hasAuthorship W2803404900A5031562823 @default.
• W2803404900 hasAuthorship W2803404900A5048320859 @default.
• W2803404900 hasAuthorship W2803404900A5054815299 @default.
• W2803404900 hasAuthorship W2803404900A5058725005 @default.
• W2803404900 hasAuthorship W2803404900A5068913631 @default.
• W2803404900 hasAuthorship W2803404900A5082888399 @default.
• W2803404900 hasBestOaLocation W28034049002 @default.
• W2803404900 hasConcept C126322002 @default.
• W2803404900 hasConcept C142724271 @default.
• W2803404900 hasConcept C202953159 @default.
• W2803404900 hasConcept C203092338 @default.
• W2803404900 hasConcept C204787440 @default.
• W2803404900 hasConcept C27081682 @default.
• W2803404900 hasConcept C2776042228 @default.
• W2803404900 hasConcept C2777014857 @default.
• W2803404900 hasConcept C2908647359 @default.
• W2803404900 hasConcept C535046627 @default.
• W2803404900 hasConcept C71924100 @default.
• W2803404900 hasConcept C99454951 @default.
• W2803404900 hasConceptScore W2803404900C126322002 @default.
• W2803404900 hasConceptScore W2803404900C142724271 @default.
• W2803404900 hasConceptScore W2803404900C202953159 @default.
• W2803404900 hasConceptScore W2803404900C203092338 @default.
• W2803404900 hasConceptScore W2803404900C204787440 @default.
• W2803404900 hasConceptScore W2803404900C27081682 @default.
• W2803404900 hasConceptScore W2803404900C2776042228 @default.
• W2803404900 hasConceptScore W2803404900C2777014857 @default.
• W2803404900 hasConceptScore W2803404900C2908647359 @default.
• W2803404900 hasConceptScore W2803404900C535046627 @default.
• W2803404900 hasConceptScore W2803404900C71924100 @default.

• next